ERCC4

DNA repair endonuclease XPF (EC 3.1.-.-) (DNA

16,538 patent compounds predicted against ERCC4, 10,712 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL107237	0.81	15/20
SCHEMBL175299	0.66	15/20
SCHEMBL107288	0.66	15/20
SCHEMBL339753	0.59	14/20
SCHEMBL107165	0.73	13/20
SCHEMBL107880	0.60	12/20
SCHEMBL108637	0.60	12/20
SCHEMBL141914	0.60	12/20
SCHEMBL108628	0.79	11/20
SCHEMBL108102	0.82	10/20
SCHEMBL107157	0.76	9/20
SCHEMBL108218	0.78	8/20
SCHEMBL912290	0.47	8/20
SCHEMBL898314	0.59	7/20
SCHEMBL1421097	0.43	7/20
SCHEMBL138689	0.56	6/20
SCHEMBL108018	0.55	5/20
SCHEMBL42351	0.48	5/20
SCHEMBL1143282	0.61	4/20
SCHEMBL851008	0.60	4/20

Germline variants in ERCC4 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ERCC4 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ERCC4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer	PHASE2	UNKNOWN
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction	PHASE2	COMPLETED
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer	PHASE2	WITHDRAWN
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy	PHASE2	COMPLETED
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer	PHASE2	COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma	PHASE1/PHASE2	RECRUITING
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer	PHASE2	COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer	PHASE2	WITHDRAWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.	nan	UNKNOWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel	nan	COMPLETED
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy	nan	COMPLETED
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
Natural History Study for DNA Repair Disorders	nan	RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ERCC4 binder may also engage these)

Protein	Name	Similarity
Q9QYM7	—	1.000	Q9QYM7 →
Q9QZD4	—	1.000	Q9QZD4 →
Q6NYU2	—	0.978	Q6NYU2 →
Q9H269	—	0.977	Q9H269 →
Q5E9L7	—	0.976	Q5E9L7 →
Q8BPM2	—	0.975	Q8BPM2 →
Q8QFR2	—	0.974	Q8QFR2 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.974	landscape →
E9Q4Z2	—	0.974	E9Q4Z2 →
Q920Q4	—	0.974	Q920Q4 →
Q5RGJ5	—	0.972	Q5RGJ5 →
P82922	—	0.972	P82922 →
O00291	—	0.972	O00291 →
Q5ZJV4	—	0.971	Q5ZJV4 →
Q60HG1	—	0.971	Q60HG1 →
Q5R8R4	—	0.971	Q5R8R4 →
Q9SV20	—	0.971	Q9SV20 →
P49135	—	0.971	P49135 →
Q9ER88	—	0.971	Q9ER88 →
Q91W86	—	0.971	Q91W86 →
P97789	—	0.971	P97789 →
P23116	—	0.970	P23116 →
Q641Y5	—	0.970	Q641Y5 →
Q7ZY60	—	0.970	Q7ZY60 →
Q6DFF4	—	0.970	Q6DFF4 →
Q1RMT1	—	0.970	Q1RMT1 →
Q6P4T2	—	0.970	Q6P4T2 →
Q5ZKK7	—	0.970	Q5ZKK7 →
A4GWN3	—	0.970	A4GWN3 →
Q9JKY5	—	0.970	Q9JKY5 →